PRIMAXIN (imipenem and cilastatin sodium) by Merck & Co. is (i. Approved for the following serious infections caused by designated susceptible bacteria: lower respiratory tract infections, lower respiratory tract infections caused by susceptible strains of staphylococcus aureus (penicillinase-producing isolates), acinetobacter species and 37 more indications. First approved in 1985.
Drug data last refreshed 17h ago · AI intelligence enriched 1mo ago
PRIMAXIN is an intravenous combination antibiotic containing imipenem (a broad-spectrum penem) and cilastatin (a renal dehydropeptidase inhibitor). It treats serious infections across respiratory, urinary, intra-abdominal, gynecologic, bone/joint, skin, and bloodstream sites caused by diverse gram-positive and gram-negative bacteria. Cilastatin prevents imipenem's renal metabolism, maintaining therapeutic levels.
Limited commercial growth opportunity; teams are focused on defending market share against newer carbapenems and beta-lactam/beta-lactamase inhibitor combinations in a consolidating hospital market.
(I.V.) is a combination of imipenem and cilastatin. Imipenem is a penem antibacterial drug [see Microbiology ( )] . Cilastatin is a renal dehydropeptidase inhibitor that limits the renal metabolism of imipenem.
Worked on PRIMAXIN at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moPRIMAXIN offers limited career growth; roles are defensive and contract-focused rather than strategic. Professionals on this brand typically manage declining markets, negotiate rebates, and maintain compliance—skill-building that transfers well to generics or biosimilar launches but lacks the prestige of peak-lifecycle growth products.